The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
- Author:
Yen Hsiang HUANG
1
;
Kuo Hsuan HSU
;
Jeng Sen TSENG
;
Kun Chieh CHEN
;
Chia Hung HSU
;
Kang Yi SU
;
Jeremy J W CHEN
;
Huei Wen CHEN
;
Sung Liang YU
;
Tsung Ying YANG
;
Gee Chen CHANG
Author Information
- Publication Type:Original Article
- Keywords: Lung neoplasms; Adenocarcinoma; Epidermal growth factor receptor mutation; T790M; Exon 19 deletion
- MeSH: Adenocarcinoma*; Disease-Free Survival; Epidermal Growth Factor*; Exons; Humans; Lung Neoplasms; Lung*; Mutation Rate; Odds Ratio; Phosphotransferases; Point Mutation; Prevalence; Receptor, Epidermal Growth Factor*; Sequence Deletion
- From:Cancer Research and Treatment 2018;50(4):1294-1303
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The main objective of this study was to investigate the relationship among the clinical characteristics and the frequency of T790M mutation in advanced epidermal growth factor receptor (EGFR)–mutant lung adenocarcinoma patients with acquired resistance after firstline EGFR–tyrosine kinase inhibitor (TKI) treatment. MATERIALS AND METHODS: We enrolled EGFR-mutant stage IIIB-IV lung adenocarcinoma patients, who had progressed to prior EGFR-TKI therapy, and evaluated their rebiopsy EGFR mutation status. RESULTS: A total of 205 patients were enrolled for analysis. The overall T790M mutation rate of rebiopsy was 46.3%. The T790M mutation rates among patients with exon 19 deletion mutation, exon 21 L858R point mutation, and other mutations were 55.0%, 37.3%, and 27.3%, respectively. Baseline exon 19 deletion was associated with a significantly higher frequency of T790M mutation (adjusted odds ratio, 2.14; 95% confidence interval [CI], 1.20 to 3.83; p=0.010). In the exon 19 deletion subgroup, there was a greater prevalence of T790M mutation than other exon 19 deletion subtypes in patients with the Del E746-A750 mutation (61.6% vs. 40.6%; odds ratio, 2.35; 95% CI, 1.01 to 5.49; p=0.049). The progression-free survival (PFS) of first-line TKI treatment > 11 months was also associated with a higher T790M mutation rate (54.1% vs. 39.3%; adjusted odds ratio, 1.82; 95% CI, 1.02 to 3.25; p=0.044). Patients who underwent rebiopsy at metastatic sites had more chance to harbor T790M mutation (52.6% vs. 33.8%; adjusted odds ratio, 1.97; 95% CI, 1.06 to 3.67; p=0.032). CONCLUSION: PFS of first-line EGFR-TKI, rebiopsy site, EGFR exon 19 deletion and its subtype Del E746-A750 mutation are associated with the frequency of T790M mutation.
